• Natera joined Alliance Foundation Trials, Genentech to launch AFT-70 NAVIGATE, a global Phase III breast cancer study using Signatera-guided treatment.
• No trial results have been presented; the study will test whether MRD monitoring can safely limit CDK4/6 inhibitor use.
• Strategy uses giredestrant as the endocrine backbone, adding a CDK4/6 inhibitor only if Signatera detects residual disease.
• Enrollment target exceeds 2,000 stage II-III ER-positive, HER2-negative patients across roughly 200 sites in the U.S. and abroad.
• Focus is maintaining recurrence outcomes while reducing exposure to added therapy burdens, supporting a more selective adjuvant treatment approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261005157854) on October 05, 2026, and is solely responsible for the information contained therein.